Routine follow-up after treatment for a gynecological cancer: a survey of practice
The objective of this study was to determine current practice with regards to follow-up after gynecological malignancy. A questionnaire survey of all lead clinicians in gynecological cancer centers in England was done. The most common duration of routine follow-up was 5 years for all of the main gyn...
Gespeichert in:
| Veröffentlicht in: | International journal of gynecological cancer 2006, Vol.16 (1), p.380-384 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 384 |
|---|---|
| container_issue | 1 |
| container_start_page | 380 |
| container_title | International journal of gynecological cancer |
| container_volume | 16 |
| creator | Kew, F. M. Cruickshank, D. J. |
| description | The objective of this study was to determine current practice with regards to follow-up after gynecological malignancy. A questionnaire survey of all lead clinicians in gynecological cancer centers in England was done. The most common duration of routine follow-up was 5 years for all of the main gynecological cancers (ovarian, endometrial, vulval, and cervical). The most common follow-up patterns were three monthly for 2 years then six monthly for 3 years after ovarian cancer; three monthly for the first year, four monthly for the second year, six monthly for the third year then annually for 1 year after endometrial cancer; three monthly for the first year, four monthly for the second year, six monthly for the third and fourth years, then annually for 1 year after vulval cancer; three monthly for the first year, four monthly for the second year, six monthly for the third and fourth years, then annually for 1 year after cervical cancer. The test for CA125 was routinely performed by 67% of cancer networks to detect recurrence after ovarian cancer. Routine follow-up after gynecological cancer continues to be standard practice, despite limited evidence to support its use. Prospective research is needed to determine best practice. |
| doi_str_mv | 10.1136/ijgc-00009577-200601000-00061 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70731223</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1048891X24151730</els_id><sourcerecordid>70731223</sourcerecordid><originalsourceid>FETCH-LOGICAL-b3541-e806ea256f27c60fdd564331cffcbcf8b4900cfb793fd8047bbba79790d7a1a53</originalsourceid><addsrcrecordid>eNqVkV1rFDEUhoNY7If-BRkQvRtNMvmYEbwoRWuhUCgK3oVM5mSbNTNZk0yX_fdmO6sFQdDcnOTkfU_OeYLQa4LfEtKId269MjUuq-NS1hRjgUk57VOCPEEnhFNeE9a0T8ses7ZuO_LtGJ2mtN6bKO6eoWMiGONC0BN0exvm7CaobPA-bOt5U2mbIVY5gs4jTLncxEpXq90EJviwckb7yujJQHxf8mmO97Crgq02UZvsDDxHR1b7BC8O8Qx9_fTxy8Xn-vrm8uri_LruG85IDS0WoCkXlkojsB0GLljTEGOt6Y1te9ZhbGwvu8YOLWay73stO9nhQWqieXOG3ix1NzH8mCFlNbpkwHs9QZiTklg2hNKmCF_9IVyHOU6lN0U5py3pCtii-rCoTAwpRbBqE92o404RrPbo1R69-oVe_UavHtAX_8vDK3M_wvDoPrAuArYItsEXwum7n7cQ1R1on-_U37602C4XGxSW9644knFQ8A8ugslqCO6fO2yXSv24_s_hfgJSSrY-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2552819136</pqid></control><display><type>article</type><title>Routine follow-up after treatment for a gynecological cancer: a survey of practice</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Kew, F. M. ; Cruickshank, D. J.</creator><creatorcontrib>Kew, F. M. ; Cruickshank, D. J.</creatorcontrib><description>The objective of this study was to determine current practice with regards to follow-up after gynecological malignancy. A questionnaire survey of all lead clinicians in gynecological cancer centers in England was done. The most common duration of routine follow-up was 5 years for all of the main gynecological cancers (ovarian, endometrial, vulval, and cervical). The most common follow-up patterns were three monthly for 2 years then six monthly for 3 years after ovarian cancer; three monthly for the first year, four monthly for the second year, six monthly for the third year then annually for 1 year after endometrial cancer; three monthly for the first year, four monthly for the second year, six monthly for the third and fourth years, then annually for 1 year after vulval cancer; three monthly for the first year, four monthly for the second year, six monthly for the third and fourth years, then annually for 1 year after cervical cancer. The test for CA125 was routinely performed by 67% of cancer networks to detect recurrence after ovarian cancer. Routine follow-up after gynecological cancer continues to be standard practice, despite limited evidence to support its use. Prospective research is needed to determine best practice.</description><identifier>ISSN: 1048-891X</identifier><identifier>EISSN: 1525-1438</identifier><identifier>DOI: 10.1136/ijgc-00009577-200601000-00061</identifier><identifier>PMID: 16445662</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>Cervical cancer ; Chemotherapy, Adjuvant ; Combined Modality Therapy ; Continuity of Patient Care - standards ; Continuity of Patient Care - trends ; Diagnostic Tests, Routine ; Endometrial cancer ; Female ; follow-up ; Follow-Up Studies ; Genital cancers ; Genital Neoplasms, Female - diagnosis ; Genital Neoplasms, Female - therapy ; Gynecologic Surgical Procedures - standards ; Gynecologic Surgical Procedures - trends ; Gynecological cancer ; gynecological malignancy ; Gynecology ; Health Care Surveys ; Humans ; Male ; Ovarian cancer ; Practice Patterns, Physicians' - standards ; Practice Patterns, Physicians' - statistics & numerical data ; Practice Patterns, Physicians' - trends ; Quality of Health Care ; Radiotherapy, Adjuvant ; Risk Assessment ; survey ; Surveys and Questionnaires ; Time Factors ; United Kingdom</subject><ispartof>International journal of gynecological cancer, 2006, Vol.16 (1), p.380-384</ispartof><rights>2006, IGCS</rights><rights>2006 IGCS and ESGO.</rights><rights>Copyright © 2006 Blackwell Publishing Ltd.</rights><rights>2006 2006, IGCS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b3541-e806ea256f27c60fdd564331cffcbcf8b4900cfb793fd8047bbba79790d7a1a53</citedby><cites>FETCH-LOGICAL-b3541-e806ea256f27c60fdd564331cffcbcf8b4900cfb793fd8047bbba79790d7a1a53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4009,27902,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16445662$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kew, F. M.</creatorcontrib><creatorcontrib>Cruickshank, D. J.</creatorcontrib><title>Routine follow-up after treatment for a gynecological cancer: a survey of practice</title><title>International journal of gynecological cancer</title><addtitle>Int J Gynecol Cancer</addtitle><description>The objective of this study was to determine current practice with regards to follow-up after gynecological malignancy. A questionnaire survey of all lead clinicians in gynecological cancer centers in England was done. The most common duration of routine follow-up was 5 years for all of the main gynecological cancers (ovarian, endometrial, vulval, and cervical). The most common follow-up patterns were three monthly for 2 years then six monthly for 3 years after ovarian cancer; three monthly for the first year, four monthly for the second year, six monthly for the third year then annually for 1 year after endometrial cancer; three monthly for the first year, four monthly for the second year, six monthly for the third and fourth years, then annually for 1 year after vulval cancer; three monthly for the first year, four monthly for the second year, six monthly for the third and fourth years, then annually for 1 year after cervical cancer. The test for CA125 was routinely performed by 67% of cancer networks to detect recurrence after ovarian cancer. Routine follow-up after gynecological cancer continues to be standard practice, despite limited evidence to support its use. Prospective research is needed to determine best practice.</description><subject>Cervical cancer</subject><subject>Chemotherapy, Adjuvant</subject><subject>Combined Modality Therapy</subject><subject>Continuity of Patient Care - standards</subject><subject>Continuity of Patient Care - trends</subject><subject>Diagnostic Tests, Routine</subject><subject>Endometrial cancer</subject><subject>Female</subject><subject>follow-up</subject><subject>Follow-Up Studies</subject><subject>Genital cancers</subject><subject>Genital Neoplasms, Female - diagnosis</subject><subject>Genital Neoplasms, Female - therapy</subject><subject>Gynecologic Surgical Procedures - standards</subject><subject>Gynecologic Surgical Procedures - trends</subject><subject>Gynecological cancer</subject><subject>gynecological malignancy</subject><subject>Gynecology</subject><subject>Health Care Surveys</subject><subject>Humans</subject><subject>Male</subject><subject>Ovarian cancer</subject><subject>Practice Patterns, Physicians' - standards</subject><subject>Practice Patterns, Physicians' - statistics & numerical data</subject><subject>Practice Patterns, Physicians' - trends</subject><subject>Quality of Health Care</subject><subject>Radiotherapy, Adjuvant</subject><subject>Risk Assessment</subject><subject>survey</subject><subject>Surveys and Questionnaires</subject><subject>Time Factors</subject><subject>United Kingdom</subject><issn>1048-891X</issn><issn>1525-1438</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqVkV1rFDEUhoNY7If-BRkQvRtNMvmYEbwoRWuhUCgK3oVM5mSbNTNZk0yX_fdmO6sFQdDcnOTkfU_OeYLQa4LfEtKId269MjUuq-NS1hRjgUk57VOCPEEnhFNeE9a0T8ses7ZuO_LtGJ2mtN6bKO6eoWMiGONC0BN0exvm7CaobPA-bOt5U2mbIVY5gs4jTLncxEpXq90EJviwckb7yujJQHxf8mmO97Crgq02UZvsDDxHR1b7BC8O8Qx9_fTxy8Xn-vrm8uri_LruG85IDS0WoCkXlkojsB0GLljTEGOt6Y1te9ZhbGwvu8YOLWay73stO9nhQWqieXOG3ix1NzH8mCFlNbpkwHs9QZiTklg2hNKmCF_9IVyHOU6lN0U5py3pCtii-rCoTAwpRbBqE92o404RrPbo1R69-oVe_UavHtAX_8vDK3M_wvDoPrAuArYItsEXwum7n7cQ1R1on-_U37602C4XGxSW9644knFQ8A8ugslqCO6fO2yXSv24_s_hfgJSSrY-</recordid><startdate>2006</startdate><enddate>2006</enddate><creator>Kew, F. M.</creator><creator>Cruickshank, D. J.</creator><general>Elsevier Inc</general><general>Copyright Blackwell Publishing Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>2006</creationdate><title>Routine follow-up after treatment for a gynecological cancer: a survey of practice</title><author>Kew, F. M. ; Cruickshank, D. J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b3541-e806ea256f27c60fdd564331cffcbcf8b4900cfb793fd8047bbba79790d7a1a53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Cervical cancer</topic><topic>Chemotherapy, Adjuvant</topic><topic>Combined Modality Therapy</topic><topic>Continuity of Patient Care - standards</topic><topic>Continuity of Patient Care - trends</topic><topic>Diagnostic Tests, Routine</topic><topic>Endometrial cancer</topic><topic>Female</topic><topic>follow-up</topic><topic>Follow-Up Studies</topic><topic>Genital cancers</topic><topic>Genital Neoplasms, Female - diagnosis</topic><topic>Genital Neoplasms, Female - therapy</topic><topic>Gynecologic Surgical Procedures - standards</topic><topic>Gynecologic Surgical Procedures - trends</topic><topic>Gynecological cancer</topic><topic>gynecological malignancy</topic><topic>Gynecology</topic><topic>Health Care Surveys</topic><topic>Humans</topic><topic>Male</topic><topic>Ovarian cancer</topic><topic>Practice Patterns, Physicians' - standards</topic><topic>Practice Patterns, Physicians' - statistics & numerical data</topic><topic>Practice Patterns, Physicians' - trends</topic><topic>Quality of Health Care</topic><topic>Radiotherapy, Adjuvant</topic><topic>Risk Assessment</topic><topic>survey</topic><topic>Surveys and Questionnaires</topic><topic>Time Factors</topic><topic>United Kingdom</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kew, F. M.</creatorcontrib><creatorcontrib>Cruickshank, D. J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of gynecological cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kew, F. M.</au><au>Cruickshank, D. J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Routine follow-up after treatment for a gynecological cancer: a survey of practice</atitle><jtitle>International journal of gynecological cancer</jtitle><addtitle>Int J Gynecol Cancer</addtitle><date>2006</date><risdate>2006</risdate><volume>16</volume><issue>1</issue><spage>380</spage><epage>384</epage><pages>380-384</pages><issn>1048-891X</issn><eissn>1525-1438</eissn><abstract>The objective of this study was to determine current practice with regards to follow-up after gynecological malignancy. A questionnaire survey of all lead clinicians in gynecological cancer centers in England was done. The most common duration of routine follow-up was 5 years for all of the main gynecological cancers (ovarian, endometrial, vulval, and cervical). The most common follow-up patterns were three monthly for 2 years then six monthly for 3 years after ovarian cancer; three monthly for the first year, four monthly for the second year, six monthly for the third year then annually for 1 year after endometrial cancer; three monthly for the first year, four monthly for the second year, six monthly for the third and fourth years, then annually for 1 year after vulval cancer; three monthly for the first year, four monthly for the second year, six monthly for the third and fourth years, then annually for 1 year after cervical cancer. The test for CA125 was routinely performed by 67% of cancer networks to detect recurrence after ovarian cancer. Routine follow-up after gynecological cancer continues to be standard practice, despite limited evidence to support its use. Prospective research is needed to determine best practice.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>16445662</pmid><doi>10.1136/ijgc-00009577-200601000-00061</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1048-891X |
| ispartof | International journal of gynecological cancer, 2006, Vol.16 (1), p.380-384 |
| issn | 1048-891X 1525-1438 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70731223 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Cervical cancer Chemotherapy, Adjuvant Combined Modality Therapy Continuity of Patient Care - standards Continuity of Patient Care - trends Diagnostic Tests, Routine Endometrial cancer Female follow-up Follow-Up Studies Genital cancers Genital Neoplasms, Female - diagnosis Genital Neoplasms, Female - therapy Gynecologic Surgical Procedures - standards Gynecologic Surgical Procedures - trends Gynecological cancer gynecological malignancy Gynecology Health Care Surveys Humans Male Ovarian cancer Practice Patterns, Physicians' - standards Practice Patterns, Physicians' - statistics & numerical data Practice Patterns, Physicians' - trends Quality of Health Care Radiotherapy, Adjuvant Risk Assessment survey Surveys and Questionnaires Time Factors United Kingdom |
| title | Routine follow-up after treatment for a gynecological cancer: a survey of practice |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T04%3A54%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Routine%20follow-up%20after%20treatment%20for%20a%20gynecological%20cancer:%20a%20survey%20of%20practice&rft.jtitle=International%20journal%20of%20gynecological%20cancer&rft.au=Kew,%20F.%20M.&rft.date=2006&rft.volume=16&rft.issue=1&rft.spage=380&rft.epage=384&rft.pages=380-384&rft.issn=1048-891X&rft.eissn=1525-1438&rft_id=info:doi/10.1136/ijgc-00009577-200601000-00061&rft_dat=%3Cproquest_cross%3E70731223%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2552819136&rft_id=info:pmid/16445662&rft_els_id=S1048891X24151730&rfr_iscdi=true |